These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 28581362)

  • 21. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
    Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.
    Kapadia R; Yi JH; Vemuganti R
    Front Biosci; 2008 Jan; 13():1813-26. PubMed ID: 17981670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
    Wagner N; Wagner KD
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
    Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of PPAR in cardiovascular diseases.
    Das SK; Chakrabarti R
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):193-209. PubMed ID: 18221086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of peroxisome proliferator-activated receptor beta/delta in chicken adipogenesis.
    Sato K; Yonemura T; Ishii H; Toyomizu M; Kamada T; Akiba Y
    Comp Biochem Physiol A Mol Integr Physiol; 2009 Nov; 154(3):370-5. PubMed ID: 19619666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling.
    Ament Z; West JA; Stanley E; Ashmore T; Roberts LD; Wright J; Nicholls AW; Griffin JL
    Free Radic Biol Med; 2016 Jun; 95():357-68. PubMed ID: 26654758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
    Ciudin A; Hernandez C; Simó R
    Curr Top Med Chem; 2012; 12(6):585-604. PubMed ID: 22242856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARbeta/delta ligands as modulators of the inflammatory response.
    Kilgore KS; Billin AN
    Curr Opin Investig Drugs; 2008 May; 9(5):463-9. PubMed ID: 18465655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression.
    Selva DM; Hammond GL
    Endocrinology; 2009 May; 150(5):2183-9. PubMed ID: 19179433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
    Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
    Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
    Ahsan W
    Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
    Dumasia R; Eagle KA; Kline-Rogers E; May N; Cho L; Mukherjee D
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):377-86. PubMed ID: 16248830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.